More News

09 May 2022 Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
09 May 2022 OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
04 May 2022 Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
04 May 2022 Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
02 May 2022 Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
01 May 2022 Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
01 May 2022 Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany
26 Apr 2022 ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
26 Apr 2022 Update on Regulatory Submission for Aducanumab in the European Union
20 Apr 2022 VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
20 Apr 2022 Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 2022 Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
14 Apr 2022 Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation
13 Apr 2022 Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
13 Apr 2022 Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
13 Apr 2022 GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
13 Apr 2022 Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss
08 Apr 2022 Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
08 Apr 2022 TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
08 Apr 2022 Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
07 Apr 2022 HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
07 Apr 2022 Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
07 Apr 2022 ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
07 Apr 2022 Almirall announces a new research collaboration with the University of Dundee to develop an innovative and differentiated treatment approach for dermatological diseases
07 Apr 2022 Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up